- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02745912
Study to Evaluate the Effect of Naltrexone and Bupropion Combination on the Pharmacokinetics of Metformin in Healthy Participants
A Phase 1, Open-Label, Sequential Design Study to Evaluate the Potential Effect of Multiple Oral Doses of Extended-Release Combination of Naltrexone and Bupropion on the Pharmacokinetics of a Single Oral Dose of Metformin in Healthy Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The drug being tested in this study is naltrexone HCl and bupropion HCl Extended- Release fixed dose combination (NB) . This study will evaluate the potential effect of multiple oral doses of extended-release combination of naltrexone/bupropion on the PK of a single oral dose of metformin in healthy participants with normal renal function (defined as creatinine clearance [CrCl] greater than equal to [>=] 90 milliliter per minute [mL/min]/1.73 meter square [m^2]).
The study will enroll approximately 30 participants. Participants will receive:
Metformin 850 mg as a single dose alone and in combination with multiple doses of Naltrexone/Bupropion Naltrexone 8 mg/Bupropion 90 mg + Naltrexone 16 mg/Bupropion 180 mg as multiple doses alone and in combination with a single dose of metformin
All participants will be asked to take 1 tablet of metformin in the morning on Day 1 and Day 14, 1 tablet of naltrexone/bupropion twice daily from Day 3 through Day 5, and 2 tablets of naltrexone/bupropion twice daily from Day 6 through Day 15.
This single center trial will be conducted in the United States. The overall time to participate in this study is 73 days. Participants will be admitted on Day -1 (check in) and remain confined to the clinic until Day 16 and will be contacted by telephone 30 (±2) days after last dose of study drug for a follow-up assessment. Serial blood samples will be collected for PK assessments. Safety will be monitored throughout the study.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Is a healthy male or female.
- Is aged 18 to 55 years, inclusive, at signing of informed consent and first dose of study drug.
- Weighs at least 50 kilogram (kg) and has a body mass index (BMI) of 18.0 to 40.0 kilogram per square meter (kg/m^2), inclusive, at Screening.
- Has normal renal function (defined as CrCl >=90 mL/min/1.73 m^2) at Screening and Check-in (Day -1).
- A female subject of childbearing potential* who is sexually active with a nonsterilized* male partner agrees to use adequate contraception* from signing of informed consent throughout the duration of the study and for 12 weeks after the last dose of study drug.
Exclusion Criteria:
- Has known hypersensitivity to metformin, bupropion, naltrexone, or any component of the formulations.
- Has history of seizure of any etiology, or of predisposition to seizures.
- Has history of bulimia.
- Has history of anorexia nervosa.
- Has resting heart rate outside the normal range of 45 to 100 beats per minutes at Screening or Check-in (Day -1) and confirmed by a repeat measurement approximately 30 minutes following the initial measurement.
- Has orthostatic blood pressure >=25 millimeter of mercury (mm Hg) at Screening or Check-in (Day -1) and confirmed by a repeat measurement approximately 30 minutes following the initial measurement.
- Has sustained supine systolic blood pressure >=140 mm Hg or less than equal to (<=) 90 mm Hg or a diastolic blood pressure >=90 mm Hg or <=50 mm Hg at Screening or Check-in (Day -1) and confirmed by a repeat measurement approximately 30 minutes following the initial measurement.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Metformin + Naltrexone/Bupropion
Metformin (850 mg, immediate release tablet, orally, once on Day 1 and Day 14) naltrexone/bupropion (8/90 mg/mg, extended-release tablets, orally, twice daily from Day 3 through Day 5 and 16/180 mg/mg, twice daily from Day 6 through Day 15.
|
Naltrexone/Bupropion extended-release tablets.
Metformin immediate-release tablet.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cmax: Maximum Observed Plasma Concentration for Metformin Following a Single Dose of Metformin Administered Alone
Time Frame: Day 1: predose and at multiple timepoints (up to 48 hours) post-dose
|
Day 1: predose and at multiple timepoints (up to 48 hours) post-dose
|
Cmax: Maximum Observed Plasma Concentration of Metformin Following a Single Dose of Metformin and multiple Doses of naltrexone/bupropion
Time Frame: Day 14: predose and at multiple timepoints (up to 48 hours) post-dose
|
Day 14: predose and at multiple timepoints (up to 48 hours) post-dose
|
AUC(0-inf): Area Under the Plasma Concentration-time Curve from Time 0 to Infinity of Metformin Following a Single Dose of Metformin Administered Alone
Time Frame: Day 1: predose and at multiple timepoints (up to 48 hours) post-dose
|
Day 1: predose and at multiple timepoints (up to 48 hours) post-dose
|
AUC(0-inf): Area Under the Plasma Concentration-time Curve from Time 0 to Infinity of Metformin Following a Single Dose of Metformin and Multiple Doses of naltrexone/bupropion
Time Frame: Day 14: predose and at multiple timepoints (up to 48 hours) post-dose
|
Day 14: predose and at multiple timepoints (up to 48 hours) post-dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cmax: Maximum Observed Plasma Concentration of bupropion, naltrexone and their metabolites (6beta-naltrexol, Bupropion, Hydroxybupropion, Threohydrobupropion, and Erythrohydrobupropion) following multiple doses of NB alone
Time Frame: Day 13 predose and at multiple timepoints (up to 12 hours) post-dose
|
Day 13 predose and at multiple timepoints (up to 12 hours) post-dose
|
Cmax: Maximum Observed Plasma Concentration of bupropion, naltrexone and their metabolites following multiple doses of naltrexone/bupropion and a single dose of metformin
Time Frame: Day 14: predose and at multiple timepoints (up to 12 hours) post-dose
|
Day 14: predose and at multiple timepoints (up to 12 hours) post-dose
|
AUC(0-tau): Area Under the Plasma Concentration-time Curve during a dosing interval for upropion, naltrexone and their metabolites (6beta-naltrexol, Bupropion, Hydroxybupropion, Threohydrobupropion, and Erythrohydrobupropion)
Time Frame: Day 13: predose and at multiple timepoints (up to 12 hours) post-dose for naltrexone/buprop alone, Day 14: predose and at multiple timepoints (up to 12 hours) post-dose, Day 14: predose and at multiple timepoints (up to 48 hours) post-dose
|
Day 13: predose and at multiple timepoints (up to 12 hours) post-dose for naltrexone/buprop alone, Day 14: predose and at multiple timepoints (up to 12 hours) post-dose, Day 14: predose and at multiple timepoints (up to 48 hours) post-dose
|
• Percentage of Participants who Experience at Least one Treatment Emergent Adverse Event (TEAE)
Time Frame: Day 1 upt to Day 45
|
Day 1 upt to Day 45
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Sensory System Agents
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Dopamine Agents
- Narcotic Antagonists
- Cytochrome P-450 Enzyme Inhibitors
- Antidepressive Agents, Second-Generation
- Cytochrome P-450 CYP2D6 Inhibitors
- Alcohol Deterrents
- Dopamine Uptake Inhibitors
- Naltrexone
- Bupropion
- Metformin
Other Study ID Numbers
- NaltrexBuprop-1004
- U1111-1166-8630 (Other Identifier: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Healthy Subjects | ImmunosuppressionUnited States
-
Lund UniversityCompletedHealthy Subjects | Diet, HealthySweden
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Shouyao Holdings (Beijing) Co. LTDNot yet recruiting
-
Abbisko Therapeutics Co, LtdNot yet recruiting
-
Vigonvita Life SciencesNot yet recruiting
Clinical Trials on Naltrexone/Bupropion
-
TakedaWithdrawnWeight Regain Post Bariatric SurgeryUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Breast Cancer Research Foundation; American Institute for Cancer Research; Hopkins-WellSpan...Active, not recruitingBreast Cancer | Overweight or ObesityUnited States
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedBinge-Eating DisorderUnited States
-
University of California, Los AngelesWithdrawnADHD | Cognitive Function | Relapse | Stimulant UseUnited States
-
St. Joseph's Healthcare HamiltonBausch Health, Canada Inc.Active, not recruiting
-
Orexigen Therapeutics, IncCompleted
-
Orexigen Therapeutics, IncCompletedObesity | OverweightUnited States
-
St. Joseph's Healthcare HamiltonBausch Health, Canada Inc.Active, not recruiting
-
University of Texas Southwestern Medical CenterNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCCompletedMethamphetamine Use DisorderUnited States
-
Oslo University HospitalOrexigen Therapeutics, IncWithdrawn